HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Applied immunohistochemistry & molecular morphology (Print)

• Publication date

  2015-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/PAI.0000000000000136PMID 25611242
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.

  2014cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2014cited by this paper
• HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

  2014cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis

  2013cited by this paper
• ‘Genetic heterogeneity’ in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases

  2012cited by this paper
• Genetics and molecular pathology of gastric malignancy: Development of targeted therapies in the era of personalized medicine.

  2012cited by this paper
• HER2 testing in gastric cancer: a practical approach

  2012cited by this paper
• HER2 genetic heterogeneity in breast carcinoma

  2011cited by this paper
• HER2 Testing in Gastric Cancer

  2011cited by this paper
• Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.

  2011cited by this paper
• Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens

  2011cited by this paper
• Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections *

  2011cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.

  2009cited by this paper
• Assessment of a HER2 scoring system for gastric cancer: results from a validation study

  2008cited by this paper
• Python for Scientific Computing

  2007cited by this paper

• HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab emtansine therapy in recurrent high-grade endometrial cancer.

  2023cites this paper
• HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies

  2020cites this paper
• Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)

  2018cites this paper
• Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression

  2018cites this paper
• Development of biomarkers for the risk stratification and targeted therapy of Barrett's oesophagus and oesophageal adenocarcinoma

  2018cites this paper
• Chemotherapy for advanced gastric cancer: future perspective in Japan

  2017cites this paper
• Circulating Cell-Free Tumour DNA in the Management of Cancer

  2015cites this paper